Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)
Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019
April 2019